PRENPRO Clinical Monograph & Batch COA
Certified DCGI Formulation Literature (PDF)
PRENPRO
Streptococcus Faecalis 30 million , Clostridum Butyricum 2 million , Bacillus Mesenfricus 1 million , Lactic Acid Bacillus 50 million
PRENPRO (Streptococcus Faecalis 30 million , Clostridum Butyricum 2 million , Bacillus Mesenfricus 1 million , Lactic Acid Bacillus 50 million) is manufactured under strict WHO-GMP compliance for maximum bioavailability and therapeutic efficacy.
Clinical Pharmacology & Therapeutic Profile
Comprehensive therapeutic guidelines for medical practitioners and institutional procurement
Therapeutic Indications
Mechanism of Action (MOA)
The active pharmacological principles in PRENPRO deliver targeted therapeutic action through standardized systemic bioavailability and verified pharmacodynamics.
As directed by the registered medical practitioner. Strictly adhere to full course duration.
Well tolerated under clinical supervision. Contraindicated in patients with hypersensitivity to active ingredients.
Store below 25°C in a dry place. Protect from moisture and direct sunlight.
WHO-GMP Certified Purity
Manufactured in state-of-the-art HVAC controlled cleanrooms with 100% active ingredient bio-potency and analytical batch testing.
Alu-Alu Moisture Barrier
Superior barrier protection against tropical humidity, preventing physical degradation and guaranteeing 24-month stability.
Exclusive District Monopoly
Strict PCD franchise monopoly allocation ensuring zero price competition and complete territory protection for our partners.
Technical Product Specifications
Active Medical Composition
PRENPRO features Streptococcus Faecalis 30 million , Clostridum Butyricum 2 million , Bacillus Mesenfricus 1 million , Lactic Acid Bacillus 50 million prepared to high pharmaceutical purity standards.
*Disclaimer: Formulations are intended solely for distribution to licensed practitioners, hospitals, and pharmacies. Dosage must adhere to medical advice.
Customer & Clinical Reviews
Real feedback from registered physicians, stockists, PCD franchise partners, and verified buyers.
Based on 1 verified review
Stocked consistently in our ethical for PRENPRO
PRENPRO has been stocked consistently in our ethical distribution warehouse, with post-treatment assessments confirming robust clinical outcomes and satisfaction. The blister foil seals are robust, keeping each unit securely protected from ambient moisture. Highly recommended for healthcare professionals seeking certified manufacturing consistency.
Questions Regarding PRENPRO
What is the therapeutic indication and composition of PRENPRO?
PRENPRO contains Streptococcus Faecalis 30 million , Clostridum Butyricum 2 million , Bacillus Mesenfricus 1 million , Lactic Acid Bacillus 50 million indicated for Indicated for therapeutic management within specified clinical indications under qualified physician guidance. as formulated by Sygnus Biotech.
What packaging presentations are available for PRENPRO?
PRENPRO is supplied in tamper-evident 10 x 10 Alu-Alu / Blister Pack, engineered with barrier foil protection to ensure a 24 to 36 month shelf life.
Is monopoly PCD franchise territory available for PRENPRO?
Yes, Sygnus Biotech grants exclusive district-wise monopoly marketing rights for PRENPRO along with promotional visual aids, product cards, and marketing support.
What is the regulatory schedule and minimum order quantity (MOQ)?
PRENPRO is categorized as Schedule H with an introductory PCD franchise MOQ of 100 units per batch.
Related Formulations in Tablet
View all Tablet →
DAIBET-G2 V
Glimepiride 2mg + Metformin Hydrochloride 500mg + Voglibose 0.2mg Bilayered
